A higher body mass index and fat mass predict the reduction of dose-intensity for docetaxel but not for epirubicin in early breast cancer chemotherapy

Authors
Publication date
1 January 2013
Publisher
International Institute of Anticancer Research

Abstract

International audienc

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Hal-Diderot

    redirect
    oaioai:HAL:hal-00936765v1
    Last time updated on 14/04/2021

    HAL - Normandie Université

    redirect
    oaioai:HAL:hal-00936765v1
    Last time updated on 20/05/2019